The Development of HPV Vaccines and the Contributions of Luminex xMAP® Technology
LUMINEX SPONSORED CONTENT

The Development of HPV Vaccines and the Contributions of Luminex xMAP® Technology

The 3 existing HPV vaccines are capable of preventing the vast majority of cervical cancers. xMAP multiplexing technology, especially the cLIA and total IgG LIA assays, has facilitated the development and clinical testing of these vaccines in a high-throughput and robust manner. These assays have facilitated the simultaneous measurement of type-specific antibodies to several HPV genotypes, and have been collectively used to measure titers in thousands of individuals. Although the vaccines have long since been approved, the multiplex assays are continuing to power studies examining long-term vaccine safety and efficacy, along with the worldwide impact of vaccination against HPV-related diseases.

Download Now

    Please fill out the information below to download the content. If you are already registered, or have requested a quote before, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

    • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.